NEW YORK (GenomeWeb News) – Randox Laboratories has agreed to a non-exclusive license for Seegene's technology for use with its biochip array platform, Seegene said today.

The agreement will give Randox access to Seegene's Dual Priming Oligo technology, which it will use to develop high-throughput diagnostic screening panels to detect a variety of pathogens that cause either respiratory or sexually transmitted diseases from one sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.